AGP Executive Report
Last update: 10 minutes agoBus Crash Response: A tourist bus accident near Munich killed 2 Filipinos and left 8 seriously hurt; Italy’s Philippine consulate says most injured have been discharged and some still need care, with officials coordinating with German hospitals. Diabetes & Heart Outcomes: Novo Nordisk reports real-world data presented in Milan that escalating Ozempic to 2 mg was linked to a 6% lower risk of major cardiovascular events versus switching to Mounjaro. Sleep & Brain Health: A new review led by Italian researchers links insomnia to higher risks of stroke, hospital admission, depression, suicidal behavior, and possible dementia. Neurodegeneration Trial Start: NewAmsterdam Pharma has dosed the first participant in a Phase 2b trial of obicetrapib for preclinical Alzheimer’s. Genetic Disease Funding: Milan biotech Aptadir Therapeutics raised €40M seed funding to develop RNA inhibitor therapies, starting with Fragile X syndrome. Local Health Tech Research: The University of Turin will use Openwater’s wearable device to study muscle blood flow and vascular responses to nervous system activity. Healthcare Infrastructure & Capacity: IMA Life North America opened a new freeze-drying equipment facility in Tonawanda to support biopharma manufacturing worldwide. Wellness Travel: Dimsi Hospitality secured permits to convert a long-empty Catania port building into a 175-room Hotel Santa Lucia with spa and wellness facilities.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
